Rezul'taty sravnitel'nogo klinicheskogo issledovaniya bezopasnosti, perenosimosti i effektivnosti preparatov Ronbetal i Betaferon
- Authors: Yakhno N.N1, Zavalishin I.A2, Kotov S.V3, Shmidt T.E1, Baydina E.V2, Dubchak L.V1, Krotenkova M.V2, Bryukhov V.V2, Par V.I4, Ivanov R.A4
-
Affiliations:
- Московской медицинской академии им. И.М.Сеченова Росздрава
- Научный центр неврологии РАМН, Москва
- Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского
- Биотехнологическая компания ЗАО «БИОКАД»
- Issue: Vol 12, No 2 (2010)
- Pages: 28-34
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/93079
- ID: 93079
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N. N Yakhno
Московской медицинской академии им. И.М.Сеченова РосздраваКлиника нервных болезней
I. A Zavalishin
Научный центр неврологии РАМН, Москва
S. V Kotov
Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского
T. E Shmidt
Московской медицинской академии им. И.М.Сеченова РосздраваКлиника нервных болезней
E. V Baydina
Научный центр неврологии РАМН, Москва
L. V Dubchak
Московской медицинской академии им. И.М.Сеченова РосздраваКлиника нервных болезней
M. V Krotenkova
Научный центр неврологии РАМН, Москва
V. V Bryukhov
Научный центр неврологии РАМН, Москва
V. I Par
Биотехнологическая компания ЗАО «БИОКАД»
R. A Ivanov
Биотехнологическая компания ЗАО «БИОКАД»
References
- Гусев Е.И., Бойко А.Н. Современные подходы к использованию бета - интерферонов в лечении рассеянного склероза. Журн. неврол. и психиатр. 2000; 11: 54–9.
- Гусев Е.И., Завалишин И.А., Бойко А.Н. Рассеянный склероз и другие демиелинизирующие заболевания. М.: Миклош, 2004.
- Новик А.А., Ионова Т.И. Исследование качества жизни в медицине. Под ред. Ю.Л.Шевченко. М.: ГЭОТАР - Мед, 2004.
- Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз. М.: Медицина, 2003.
- Bayas A, Reickmann P. Managing the Adverse Effects of Interferon - b Therapy in Multiple Sclerosis. Drug Safety 2000; 22: 149–59.
- Chiu A.W, Richert N, Ehrmantraut M et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol 2009; 66 (1): 39–43.
- Durelli L, Ogerro A, Verdun E et al. Does high - dose interferon - beta - 1b improve clinical response in more severely disabled multiple sclerosis patients? J Neurol Sci 2000; 178: 37–41.
- Durelli L, Verdun E et al. The OPTimization of interferon for MS (OPTIMS) trial: a multicenter trial comparating two different doses (250 mg and 375mg) of IFN - b1b. J Neurol Sci 2000; 178: 37–41.
- Durelli L, Verdun E, Barbero P et al. Every - one - day interferon - beta - 1b versus once - weekly interferon - beta - 1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002; 359 (9316): 1453–60.
- ЕМЕА. The rules governing medicinal products in the European Union. Investigation of Bioavailability and Bioequivalence. 1998; 3: 231–44.
- European Study Group on Interferon - b - 1b in Secondary Progressive MA. Placebo - controlled multicentre randomised trial of interferon - b1b in treatment of secondary progressive multiple sclerosis. (by Ludwig Kappos). Lancet 1998; 352: 1491–7.
- Gaines A.R, Varrichio F. Interferon beta - 1b injection site reactions and necrosis. Multiple Sclerosis 1998; 4: 70–3.
- Goodkin D.E, C.A and the North American Study Group on Interferon - beta - 1b in Secondary Progressive MS. Interferon - beta - 1b in Secondary Progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract no.LBN.004]. 52th Annual Meeting of the American Academy of Neurology Late Breakers; 2000 Apr 29–May 6, San Diego, USA. http//www.fda.gov/cder/biologics/review/ifnbchi031403r2.pdf.
- IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon - beta - 1b in the treatment of MS; final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85.
- IFNB Multiple Sclerosis Study Group. Interferon - beta - 1b is effective in relapsing - remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double - blind, placebo - controlled trial. Neurology 1993; 43: 655–61.
- Knobler R.L, Greenstein J.I, Johnson K.P et al. Systemic recombinant human interferon - b treatment of relapsing - remitting multiple sclerosis: pilot study analysis and sox-year follow - up. J Interferon Res 1993; 13 (5): 333–40.
- Lublin F.D, Whitaker J.N, Eidelman B.H et al. Management of patients receiving interferon beta - 1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12–8.
- Mc Cormack P.L, Scott L.J. Interferon - b1b. A Review of its use in Relapsing - Remitting and Secondary Progressive Multiple Sclerosis. CNS Drugs 2004; 18 (8): 521–6.
- Miller D.H, Molyneux P.D, Barker G.J et al. Effect of interferon - beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double - blind, placebo - controlled trial. European Study Group on Interferon - beta1b in secondary progressive multiple sclerosis. Ann Neurol 1999; 46 (6): 850–9.
- Mohr D.C, Goodkin D.E, Likosky W et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta - 1b: relationship to adherence to treatment. Multiple Sclerosis 1996; 2: 222–6.
- Munschauer F.E, Kinkel R.P. Managing side effects of Interferon - beta in patients with relapsing - remitting multiple sclerosis. Clin Therap 1997; 19: 883–93.
- Paty D.W, Hartung H.P, Ebers G.C et al. Management of relapsing - remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999; 6 (Suppi 1): 1–35.
- Paty D.W, Li D.K. Interferon beta - lb is effective in relapsing - remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double - blind, placebo - controlled trial. The UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662–7.
- Polman H.C, Thompson A.J, Murray T.J, Mc Donald W.I. Multiple Sclerosis: The Guide to Treatment and Management; 5th ed: 25.
- Rudick R.A, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. In «Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives». Springer - Verlag, London, 1996: 230–1.
- Walther E.U, Dang T, Hohlfeld R. Managment of side effects of beta - interferon therapy in MS. Int. MS J 1999; 5: 65–70.
- Walther E.U, Hohlfeld R Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622–33.
- Weber F, Polak T, Gunther A et al. Synergistic immunomodulatory effects of interferon - b1b and the phosphodiesterase inhibitor pentoxyfylline in patients with relapsing - remitting multiple sclerosis. Ann Neurol 1998; 44: 27–34.
- WHO MS Group. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders 1999; 2: 1–11.
- Zhao Y, Traboulsee A, Petkau A.J, Li D. Regression of new gadolinium enhancing lesion activity in relapsing - remitting multiple sclerosis. Neurology 2008; 70 (13 Pt 2): 1092–7.
- Zivadinov R, Bakshi R, Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. J Neuroimaging 2004; 14 (3): 27–35.
Supplementary files
